Breaking News
February 24, 2018 - UCLA researchers use fluorescent colored proteins to trace origin of heart cells
February 24, 2018 - Home Routines Can Boost a Child’s Readiness for School
February 24, 2018 - FDA Investigating Misuse, Abuse of Gabapentinoids
February 24, 2018 - Scientists find key proteins control risk of osteoarthritis during aging
February 24, 2018 - Izon announce the launch of the qEV2 and qEV10 Exosome Isolation columns
February 24, 2018 - New CSIRO technology can create clean drinking water
February 24, 2018 - Treating sleep-disordered breathing may improve prognosis of heart failure patients
February 24, 2018 - More boys begin school a year late than girls, study finds
February 24, 2018 - Early life exposure to green space could have beneficial effects on cognitive function
February 24, 2018 - Joint Surgery: Aspirin Equals NOAC for Post-Acute VTE Prevention
February 23, 2018 - Scientists identify new marker of arthritis in mice
February 23, 2018 - Beetroot juice supplements may benefit patients with heart failure
February 23, 2018 - New study identifies novel molecular biomarkers of preeclampsia
February 23, 2018 - Researchers discover new link between gut bacteria and obesity
February 23, 2018 - Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
February 23, 2018 - Improving Glaucoma Care: Ophthalmology Times
February 23, 2018 - Preventing dementia: The promising, the disappointing and the inconclusive
February 23, 2018 - Duke researchers show how to retrain immune system of peanut-allergy mice
February 23, 2018 - Older males could live longer with light intensity exercise, study suggests
February 23, 2018 - C-sections and gut bacteria linked to childhood obesity risk
February 23, 2018 - Asthmatics have lower degree of DNA methylation in certain immune cells
February 23, 2018 - Uniforms coated with copper nanoparticles could reduce spread of hospital infections
February 23, 2018 - What Not to Do If You Have Asthma and Want to Get Pregnant
February 23, 2018 - Deep brain stimulation may be promising Alzheimer’s treatment
February 23, 2018 - AMSBIO offers new PARPtrap Assay Kit
February 23, 2018 - New study identifies mechanisms to lengthen egg viability in worms
February 23, 2018 - Interventions to improve self-concept could be critical in treating mental health patients
February 23, 2018 - Few minutes of physical activity may lower risk of death in older men, research suggests
February 23, 2018 - Modifications in HIV test enable rapid detection of Zika virus, study states
February 23, 2018 - Could Hackers Target Heart Devices?
February 23, 2018 - Kids’ Mental Health Status Not a Factor in Gun Storage
February 23, 2018 - Revellers ready for festival drug checks, study finds
February 23, 2018 - Stanford researchers explore how enzyme changes and becomes antibiotic-resistant
February 23, 2018 - Scientists decode molecular structure of healthy huntingtin protein
February 23, 2018 - Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism
February 23, 2018 - Epigenetic changes due to normal aging process linked to cancer risk
February 23, 2018 - Evaluations of Medicaid experiments by states, CMS are weak, GAO says
February 23, 2018 - Biomarkers ID’d for Anesthesia-Related Neural Damage
February 23, 2018 - Study reveals how kidney disease happens
February 23, 2018 - Iron deficiency early in life can have long-lasting consequences for the brain
February 23, 2018 - High protein diet reduces risk of Alzheimer’s disease, research finds
February 23, 2018 - Research extends powerful capabilities of MRI to nanometer scale
February 23, 2018 - Scientists show that cutting-edge technique can efficiently sort nano-sized particles
February 23, 2018 - Dornier’s new laser innovation delivers confidence to glide through deflected scopes
February 23, 2018 - Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson’s Disease Based on Existing Pivotal Clinical Trial Data
February 23, 2018 - Bariatric Surgery Enabled Stopping Diabetes Meds
February 23, 2018 - C-sections and gut bacteria increase risk of childhood obesity
February 23, 2018 - Busting myths about diet and kidney stones
February 23, 2018 - Reformulating vaccines to prevent relapse
February 23, 2018 - Prophylactic use of haloperidol does not reduce delirium burden
February 23, 2018 - Higher prevalence of kidney stones in Southern United States
February 23, 2018 - Lithotripsy has revolutionized modern kidney stone management
February 23, 2018 - Researchers describe important step toward gene therapy for patients with Sandhoff disease
February 23, 2018 - Pain Therapeutics Resubmits New Drug Application for Remoxy ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain
February 23, 2018 - Combo Therapy Highly Active in Untreated RCC
February 23, 2018 - Boosting a key protein to help bones that won’t heal
February 23, 2018 - Advanced method holds promise for substantial improvements in breast cancer diagnosis
February 23, 2018 - MRI and machine learning could predict whether OCD patients will benefit from treatment
February 23, 2018 - Comparing low-fat and low-carb diets finds little difference
February 23, 2018 - FDA Alert: Clarithromycin (Biaxin): Drug Safety Communication
February 23, 2018 - Out of Limbo Into Bomb Scare
February 23, 2018 - Patients who achieve short-term weight loss before bariatric surgery have better outcomes
February 23, 2018 - Beetroot may reduce kidney failure risk after heart x-ray, research reveals
February 23, 2018 - Sleep disruptions in menopause correlated with hot flashes and depression
February 23, 2018 - Scientists discover new treatment approach to curb severe myocarditis
February 23, 2018 - ‘Click chemistry’ approach may improve disease-fighting properties of drugs
February 23, 2018 - NIGHTSEA and EMS team up to offer KEY Award in fluorescence stereo microscopy
February 23, 2018 - Calorie restriction improves intestinal-tissue regeneration after injury
February 23, 2018 - Tobacco Kills, No Matter How It’s Smoked: Study
February 23, 2018 - Q&A: Avindra Nath, MD | Medpage Today
February 23, 2018 - Adherence to sleep apnea treatment affects risk of hospital readmission
February 23, 2018 - Zika virus could be alternative for treatment of aggressive brain cancer
February 23, 2018 - Carbon monoxide enhances efficacy of antibiotic against stomach infection
February 23, 2018 - Study sheds light on biological mechanisms that drive rare pediatric neurogenetic disorders
February 23, 2018 - MSD and Ferring Pharmaceuticals Complete Largest Ever Clinical Trial in Postpartum Haemorrhage
February 23, 2018 - Portable ultrasound can help better detect fluid in the lungs of patients with end-stage kidney disease
February 23, 2018 - Postnova AF2000 system offers reliable characterization of trace metal colloid distribution in the environment
February 23, 2018 - Pioneering study may pave way for effective painkillers to treat neuropathic pain
February 23, 2018 - Research opens up new avenue to minimize risks of transplants
February 22, 2018 - Cabozantinib Active in Advanced Thyroid Cancer
Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1)

Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1)

image_pdfDownload PDFimage_print

CAMBRIDGE, Mass.–(BUSINESS WIRE) November 3, 2017 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive preliminary data from its ongoing Phase 1/2 study with lumasiran (formerly known as ALN-GO1), an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of Primary Hyperoxaluria Type 1 (PH1). Results were presented today at the American Society of Nephrology (ASN) Kidney Week 2017 Annual Meeting, being held October 31 to November 5, 2017 in New Orleans, Louisiana.

At ASN, Alnylam presented initial data from Part B of the Phase 1/2 study in the first two cohorts of patients with PH1 (6-19 years old) dosed with lumasiran or placebo (N=8). Part B is a randomized (3:1 drug:placebo), single-blind, placebo-controlled study in patients with PH1. Patients with relatively preserved renal function were enrolled to allow for measurement of urinary oxalate excretion as a marker for hepatic oxalate production. The reported data were as of the data cut-off date of October 3, 2017.

As compared to the one patient receiving placebo, preliminary results showed that the three patients in the first cohort – who received monthly subcutaneous doses of lumasiran at 1 mg/kg for three months – experienced greater than 50 percent decreases in urinary oxalate excretion relative to baseline. The placebo patient in the first cohort was subsequently given lumasiran at 1 mg/kg monthly for three months, and this patient experienced a similar reduction in urinary oxalate. The mean maximal reduction in urinary oxalate for all four patients in this initial low dose cohort was 66 percent, and all patients achieved urinary oxalate levels at or near the normal range. Moreover, lumasiran lowered urinary oxalate excretion below 1.1 mmol/24hrs/1.73m2 – a threshold associated with reduced progression to end-stage renal disease in clinical studies* – in all patients with baseline excretion ≥ 1.6 mmol/24hrs/1.73m2 (N=3). Patients in the second cohort are receiving monthly doses of lumasiran at 3 mg/kg or placebo for three months; this cohort is ongoing and remains blinded. Aggregate data (N=4) from Cohort 2 show a mean reduction of 47 percent in urinary oxalate output relative to baseline after the first of three doses. These initial results support the hypothesis that GO inhibition has the potential to reduce and possibly normalize levels of hepatic oxalate production, thus potentially halting PH1 disease progression.

“PH1 is a devastating disease, usually manifesting in early childhood, in which excessive hepatic oxalate production leads to renal failure and often death. In our initial study results with lumasiran in patients with PH1, we observed substantial reductions in urinary oxalate, a biomarker which is directly linked to disease pathology and has been correlated with both morbidity and disease progression. Accordingly, we believe these encouraging preliminary results validate our approach of targeting GO, a key liver enzyme in the pathway leading to excessive oxalate output in patients with PH1. Further, these results offer hope that investigational lumasiran may be a potential treatment option for patients afflicted by this life-threatening disease,” said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. “We now aim to discuss these data with regulators and advance lumasiran toward Phase 3 clinical studies, where we also plan to study patients with more severe manifestations of PH1, such as systemic oxalosis and renal failure. Indeed, we are working hard to expediently conduct the clinical studies necessary to gain a more thorough understanding of the full efficacy and safety profile of lumasiran in patients with PH1.”

“Investigational lumasiran has the potential to be a paradigm-shifting approach in the treatment of patients with PH1, a severely debilitating and ultra-rare orphan disease that typically presents in early childhood,” said Prof. Georges Deschênes, M.D., Ph.D., Hôpital Robert-Debré, an investigator in the ongoing lumasiran study. “The current standard of care for afflicted patients with advanced disease includes intensive dialysis and, ultimately, a combined liver/kidney transplant, as there are currently no approved medical interventions. Although only a small number of patients have been treated to date, the preliminary results from Part B of the study are very promising, showing evidence of oxalate reduction, and even normalization, with as few as three doses of lumasiran. With these promising initial data in patients who still have relatively healthy kidneys, the PH1 community is now interested in understanding the safety and efficacy of lumasiran in patients with more advanced disease, something that Alnylam plans to test.”

Patients in the first cohort have been monitored for up to seven months after receiving their first dose of lumasiran with no drug-related serious adverse events (SAEs) or discontinuations from study. In all patients, lumasiran was generally well tolerated and the only drug-related adverse event (AE) reported was a mild and transient injection site reaction. Five SAEs were reported in three patients, including two episodes of renal stones and a case of pyelonephritis in a patient during placebo dosing. The two remaining SAEs were a report of renal stones and a case of dehydration associated with gastroenteritis, both of which occurred after dosing with lumasiran but were not considered drug-related.

*Zhao F. et al, Clin J Am Soc Nephrol. 2016; 11(1):119-26.

About Lumasiran Phase 1/2 Study

The Phase 1/2 trial of lumasiran is a randomized, single-blind, placebo-controlled study being conducted in two parts. Part A, now complete, was a single-dose study that enrolled 32 healthy adult volunteers in four single ascending dose cohorts (N=8 per cohort, randomized 3:1 drug:placebo), with subjects receiving lumasiran at dose ranges of 0.3 to 6 mg/kg. Data previously reported on Part A of the study showed that a single dose of lumasiran was generally well tolerated in healthy adult volunteers with dose-dependent elevations in plasma and urine glycolate, demonstrating preliminary human proof of concept. Part B is a multi-dose study designed to enroll up to 24 patients with PH1 (N=4 per cohort; 3:1 randomization of drug:placebo, with delayed lumasiran dosing for placebo). The primary objective of the study is to evaluate safety and tolerability of single and multiple subcutaneous doses of lumasiran. Secondary objectives include evaluation of pharmacokinetics and clinical activity of lumasiran as measured by its effects on plasma glycolate in normal healthy volunteers and urinary oxalate levels in patients with PH1.

About Lumasiran

Formerly known as ALN-GO1, lumasiran (pronounced “lu-MAH-si-ran”) is an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for the treatment of Primary Hyperoxaluria Type 1 (PH1). Lumasiran is designed to reduce the hepatic levels of the GO enzyme, thereby depleting the substrate necessary for oxalate production, which directly contributes to the pathophysiology of PH1. Lumasiran utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. Lumasiran has received both U.S. and EU Orphan Drug Designations.

The safety and efficacy of lumasiran have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Primary Hyperoxaluria Type 1 (PH1)

PH1 is an inborn error of metabolism. Specifically, PH1 is an autosomal recessive disorder of glyoxylate metabolism, where hepatic detoxification of glyoxylate is impaired due to mutation of the AGXT gene, which encodes the liver peroxisomal alanine-glyoxylate aminotransferase (AGT) enzyme, resulting in excessive oxalate production. Excess oxalate in PH1 patients results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of recurrent kidney stones or nephrocalcinosis. Renal damage is caused by a combination of tubular toxicity from oxalate, calcium oxalate deposition in the kidneys, and urinary obstruction by calcium oxalate stones. Compromised kidney function exacerbates the disease as the excess oxalate can no longer be effectively excreted, resulting in subsequent accumulation and crystallization in bones, eyes, skin, and heart, leading to severe illness and death. About 50 percent of patients will have kidney failure by age 15, and about 80 percent will have end stage renal disease by age 30. Current treatment options for advanced disease are very limited, and include frequent renal dialysis or combined organ transplantation of liver and kidneys, a procedure with high morbidity that is limited due to organ availability. Although a small minority of patients respond to Vitamin B6 supplementation, there are no approved pharmaceutical therapies for PH1.

Alnylam – Sanofi Genzyme Alliance

In January 2014, Alnylam and Sanofi Genzyme, the specialty care global business unit of Sanofi, formed an alliance to accelerate the advancement of RNAi therapeutics as a potential new class of innovative medicines for patients around the world with rare genetic diseases. The alliance enables Sanofi Genzyme to expand its rare disease pipeline with Alnylam’s novel RNAi technology and provides access to Alnylam’s R&D engine, while Alnylam benefits from Sanofi Genzyme’s proven global capabilities to advance late-stage development and, upon commercialization, accelerate market access for these promising genetic medicine products. Sanofi Genzyme has the right to opt in to develop and commercialize lumasiran in territories outside of the United States, Canada and Western Europe and could elect to exercise its one right to a global license for lumasiran.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 600 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

Forward-Looking Statements

Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including without limitation, Alnylam’s views with respect to the potential for investigational RNAi therapeutics, including lumasiran, its expectations regarding the future development of lumasiran and its planned interactions with regulatory authorities to discuss the Phase 1/2 data and advance lumasiran into Phase 3 development, and expectations regarding its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, Alnylam’s ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all, actions or advice of regulatory agencies, which may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional pre-clinical and/or clinical testing, delays, interruptions or failures in the manufacture and supply of our product candidates, obtaining, maintaining and protecting intellectual property, Alnylam’s ability to enforce its intellectual property rights against third parties and defend its patent portfolio against challenges from third parties, obtaining and maintaining regulatory approval, pricing and reimbursement for products, progress in establishing a commercial and ex-United States infrastructure, competition from others using technology similar to Alnylam’s and others developing products for similar uses, Alnylam’s ability to manage its growth and operating expenses, obtain additional funding to support its business activities, and establish and maintain strategic business alliances and new business initiatives, Alnylam’s dependence on third parties for development, manufacture and distribution of products, the outcome of litigation, the risk of government investigations, and unexpected expenditures, as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

The scientific information discussed in this news release relating to Alnylam’s investigational therapeutic, lumasiran, is preliminary and investigative. Lumasiran has not been approved by the U.S. Food and Drug Administration, European Medicines Agency, or any other regulatory authority and no conclusions can or should be drawn regarding the safety or effectiveness of lumasiran.

Source: Alnylam Pharmaceuticals, Inc.

Posted: November 2017

Tagged with:

About author

Related Articles